Skip to main content

Day: January 23, 2024

Unicycive Therapeutics Issues Shareholder Letter to Highlight Corporate Progress and Key Upcoming Milestones

– Topline Data from OLC Pivotal Trial Expected in Q2 2024 –– OLC will target the multibillion-dollar hyperphosphatemia market – LOS ALTOS, Calif., Jan. 23, 2024 (GLOBE NEWSWIRE) — Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company or “Unicycive”), today issued a letter to shareholders. Dear Shareholders: As I sit down to write this letter, I am filled with a profound sense of gratitude and excitement, energized for the year ahead. I remain as confident as ever that the work we’re doing at Unicycive will change the treatment paradigm in kidney disease and leave a lasting impact for patients, physicians, and for you, our shareholders. When I founded Unicycive in 2016 I knew the journey we were embarking on was ambitious—to offer hope...

Continue reading

ANI Pharmaceuticals Announces the Launch of Pentoxifylline Extended-Release Tablets, USP

BAUDETTE, Minn., Jan. 23, 2024 (GLOBE NEWSWIRE) — ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of Pentoxifylline Extended-Release (ER) Tablets, USP 400mg. ANI’s Pentoxifylline ER Tablets are the generic version of the Reference Listed Drug (RLD) Trental®. The current annual U.S. market for Pentoxifylline ER Tablets is approximately $19.7 million, according to latest estimates from IQVIA/IMS Health, a leading healthcare data and analytics provider. “We are pleased to continue the momentum in our generics business with another launch into a limited competition market. ANI remains committed to driving growth through superior new product launch execution, operational excellence, cost-competitiveness, and supply reliability. With a patient-first mindset, our goal is to ensure that patients...

Continue reading

Parsons Included on $200M GSA Construction Management Contract

CHANTILLY, Va., Jan. 23, 2024 (GLOBE NEWSWIRE) — Parsons Corporation (NYSE: PSN) announced today that the company was named on a multiple award task order contract by the United States General Services Administration (GSA) Public Building Service. The estimated $200 million Blanket Purchase Agreement (BPA) for program management and construction management (PM/CM) services is new work for the company and has a five-year ordering period. Under the contract, Parsons will compete for task orders to provide pre-planning, construction management and commissioning services, among many others, to GSA for building renovations and new construction projects. “Parsons is a proven leader in the program and construction management industry with nearly 80 years of experience advancing the federal government’s infrastructure programs,” said Jon...

Continue reading

Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2023

Company AnnouncementNet sales of DARZALEX® in 2023 totaled USD 9,744 million Genmab receives royalties on worldwide net sales from Janssen Biotech, Inc. (Janssen)COPENHAGEN, Denmark; January 23, 2024 – Genmab A/S (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX® (daratumumab), including sales of the subcutaneous (SC) product (daratumumab and hyaluronidase-fihj, sold under the tradename DARZALEX FASPRO® in the U.S.), as reported by Johnson & Johnson were USD 9,744 million in 2023. Net trade sales were USD 5,277 million in the U.S. and USD 4,467 million in the rest of the world. Genmab receives royalties on the worldwide net sales of DARZALEX, both the intravenous and SC products, under the exclusive worldwide license to Janssen to develop, manufacture and commercialize daratumumab.   About Genmab Genmab...

Continue reading

KRONOS WORLDWIDE ANNOUNCES EXCHANGE OFFER AND CONSENT SOLICITATION

Dallas, Texas, Jan. 23, 2024 (GLOBE NEWSWIRE) — Kronos Worldwide, Inc. (NYSE: KRO) (the “Company”) today announced that it has commenced an offer to certain eligible holders described below to exchange up to €325 million of outstanding principal amount of 3.75% Senior Secured Notes due 2025 (the “Old Notes”) of Kronos International, Inc., the Company’s wholly-owned subsidiary (the “Issuer”), for newly issued 9.50% Senior Secured Notes due 2029 of the Issuer (the “New Notes”) plus additional cash consideration as described below, upon the terms and conditions set forth in a Confidential Exchange Offering Memorandum and Consent Solicitation Statement dated January 23, 2024 (the “Exchange Offer”). The table below summarizes the principal economic terms of the Exchange Offer.Old Notes to be Exchanged: 3.75% Senior Secured Notes...

Continue reading

Headwall Acquires inno-spec GmbH

Headwall takes significant step towards expanding its leadership in hyperspectral imaging technologies based on three strategic pillars: industrial applications, remote sensing, and optical componentsHeadwall Photonics Welcomes inno-spec GmbH to the Headwall Group of CompaniesOliver Grass, founder and CEO of inno-spec (left) and Mark Willingham, CEO of Headwall (right) shake hands as inno-spec joins the Headwall Group of companies. The acquisition combines Headwall’s cutting-edge optical components and remote sensing technologies with inno-spec’s specialized knowledge in industrial applications enabling the development of more advanced, efficient, and versatile hyperspectral imaging systems and reinforcing the company’s position as a leader in the field.Bolton, Massachusetts & Nuremberg, Germany, Jan. 23, 2024...

Continue reading

New fixed-rate bond – Nykredit Realkredit A/S

To Nasdaq Copenhagen A/S         New fixed-rate bond Nykredit opens the following new fixed-rate bond4% 30-years annuity SDO with interest-only option up to 30 years and maturity date on 1 October 2056The new bond will be used to fund lending in Totalkredit A/S and Nykredit Realkredit A/S. The Final Bond Terms will be published in separate stock exchange announcement. Questions may be addressed to Lars Mossing Madsen, tel. + 45 44 55 11 66 or Christian Mauritzen, tel. +45 44 55 10 14.AttachmentForhåndsmeddelse – UK

Continue reading

Duluth Holdings Inc. Announces Appointment of Heena Agrawal as Chief Financial Officer

Heena Agrawal, Chief Financial OfficerHeena Agrawal, Chief Financial OfficerMOUNT HOREB, Wis., Jan. 23, 2024 (GLOBE NEWSWIRE) — Duluth Holdings Inc. (dba, Duluth Trading Company) (“Duluth Trading” or the “Company”) (NASDAQ: DLTH), a lifestyle brand of men’s and women’s workwear, casual wear, outdoor apparel and accessories, today announced the appointment of Heena Agrawal as Senior Vice President and Chief Financial Officer, effective February 12, 2024.Ms. Agrawal is a proven executive with over 20 years of finance and leadership experience. She is a business-oriented finance leader with diverse, versatile skills and a track record of driving superior results for a wide variety of companies across multiple industries including Procter & Gamble, Walgreens, Underwriters Lab, and Kontoor Brands. Ms. Agrawal’s business...

Continue reading

Invoice Bazaar, a Triterras Company, Collaborates with Cari to provide Working Capital Solutions to Restaurants

This strategic alliance aims to facilitate the introduction of Invoice Bazaar’s financial services to restaurants affiliated with Cari’s food delivery platform in the United Arab Emirates DUBAI, United Arab Emirates, Jan. 23, 2024 (GLOBE NEWSWIRE) — Invoice Bazaar, a subsidiary of Triterras which is a leading fintech company focused on digital trade and supply chain finance, has announced a strategic collaboration with Rapid Cari Delivery Services, LLC (“Cari”), a prominent food delivery platform in Dubai. This agreement marks a significant step forward in empowering restaurants on Cari’s network with tailored working capital financing solutions through Invoice Bazaar’s innovative supply chain finance platform, KRATOS™. This alliance seamlessly aligns with Invoice Bazaar’s commitment to fostering economic growth...

Continue reading

DSV, 1084 – SHARE BUYBACK IN DSV A/S

Company Announcement No. 1084 On 24 October 2023, we initiated a share buyback programme, as described in Company Announcement No. 1066. According to the programme, the company will in the period from 24 October 2023 until 31 January 2024 purchase own shares up to a maximum value of DKK 2,500 million, and no more than 4,000,000 shares, corresponding to 1.83% of the share capital at commencement of the programme. The programme has been implemented in accordance with Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (“MAR”) (save for the rules on share buyback programmes set out in MAR article 5) and the Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbour rules. The following transactions have been recorded under the programme:Trading day Trading platform   Number of shares...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.